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Abstract
The prognosis of patients with systemic lupus erythematosus has
greatly improved since treatment regimens combining cortico-
steroids and immunosuppressive medications have been widely
adopted in therapeutic strategies given to these patients. Immune
suppression is evidently efficient but also leads to higher
susceptibility to infectious and malignant diseases. Toxic effects
and sometimes unexpectedly dramatic complications of current
therapies have been progressively reported. Identifying novel
molecular targets therefore remains an important issue in the treat-
ment of lupus. The aim of this review article is to highlight emerging
pharmacological options and new therapeutic avenues for lupus
with a particular focus on non-antibody molecular strategies.
Introduction
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by unpredictable exacerba-
tions and remissions with diverse clinical manifestations. The
latter may range from nonspecific symptoms, such as fatigue
and arthralgia, to life-threatening renal and neurological
manifestations. Women of childbearing age and certain
minorities are disproportionately affected. A prevalence of
several hundred thousand patients with lupus has been
estimated in the United States – it may in fact approach
1 million to 2 million individuals according to the Lupus
Foundation of America – and almost the same figures are
given in Europe.
Compared with previous decades, when the 4-year survival
was estimated to be just 50% in the 1950s, patients with
SLE today are less likely to die from the disease itself (the
15-year survival rate is now estimated to be around 80 to
85%). This notable improvement comes from the introduction
in the 1960s and 1970s of key immunosuppressive drugs
such as azathioprine, methotrexate, cyclophosphamide, and
cyclosporine, and more recently by the use of mycophenolate
mofetil (CellCept) that appears effective with fewer side
effects. At present, antimalarials (hydroxychloroquine),
corticosteroids and cytotoxic drugs are classically used as
medication in SLE. It has to be recognized, however, that
significant well-known adverse effects of these conventional
drugs may severely counterbalance the clinical outcomes of
treated patients, who can develop recurrent infections and in
some cases malignant diseases. These major side effects are
due to the generalized nature of the immunosuppression.
There are also concerns about still unpredictable lupus flares
in disease remissions and about a non-negligible number of
nonresponders sometimes affected by severe forms of lupus
such as catastrophic antiphospholipid syndrome.
For all these reasons, and particularly in the past 6 to 7 years,
intense and collective research has led to the development of
more targeted approaches that are currently under evaluation
for treating patients with lupus. A number of drugs in late-
stage clinical development hold promise for treating the
disease. These drugs are mostly mAbs targeting B cells, such
as rituxan (rituximab) or ocrelizumab (mAbs to CD20 antigen
on B cells; both in phase III trial by Genentec, San Francisco,
CA, USA), LymphoStat-B (belimumab; phase III trial by
Human Genome Sciences, Rickville, IN, USA) that targets B-
lymphocyte stimulator, and epratuzumab, a humanized
antibody (Ab) that targets the CD22 receptor on B cells
(phase IIb trial by UCB Pharma, Colombes, Belgium).
The present report will not concentrate on these therapeutic
Abs that have been described in recent comprehensive
reviews (for example [1,2]), but will rather focus on fusion
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proteins, peptides and small molecules that represent
excellent alternative tools for immune intervention in lupus.
Novel targets in the treatment of lupus
patients: ongoing therapeutic trials
Molecular targeted therapies have created an encouraging
trend in the treatment of lupus. In recent years, drugs
targeting cell surface molecules, intracellular components,
hormones or autoantigens have been clinically evaluated
(Table 1 and Additional File 1).
Cell surface-expressed molecules
Based on our improving knowledge of cellular abnormalities
in lupus, a variety of T-cell and B-cell surface-expressed
molecules can conceptually be targeted to bypass or correct
these dysfunctions. In addition to mAbs that target key cell-
surface markers such as CD3, CD4, CD20, CD22, CD25
(IL-2 receptor alpha), CD52 (present on the surface of
mature lymphocytes), CD40 and CD154/CD40 ligand or
certain integrins, therefore, potentially efficient molecules
have been developed to interfere with cell-surface compo-
nents, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4)/
CD152, certain members of the TNF family or members of
the heat shock protein family.
Abatacept (CTLA-4 immunoglobulin; Orencia, developed by
Bristol-Myers-Squibb, Princeton, NJ, USA) is a fusion protein
that contains the extracellular domain of the co-stimulator
receptor CTLA-4 molecule and an IgG Fc domain. Abatacept
is thought to inhibit stimulation of T cells by blocking the
interaction of CD80/CD86 (B7-1/B7-2) with CD28
(Figure 1). This drug, which is approved to treat rheumatoid
arthritis, has been evaluated in association with prednisone in
a phase IIb clinical trial for SLE, and a phase III trial for SLE is
currently recruiting participants. The same company also
develops belatacept (LEA29Y), which differs from abatacept
by only two amino acid residues.
Atacicept, a TACI-Ig fusion protein currently evaluated in
placebo-controlled phase II/III clinical trials under the
sponsorshop of Zymogenetics/Merck Serono (Seattle, WA,
USA and Geneva, Switzerland), targets B-lymphocyte stimu-
lator and APRIL, two members of the TNF family, which
promote B-cell survival. In an earlier phase Ib trial, patients
treated with atacicept demonstrated dose-related decreases
in immunoglobulin and in mature and total B-cell numbers.
There was no change in the numbers of T cells, natural killer
cells, or monocytes. The drug was shown to be safe and well
tolerated with no serious adverse effects. There was also a
positive trend in SELENA – Systemic Lupus Erythematosus
Disease Activity Index (SLEDAI) scores and in complement
levels in treated patients [3].
Intensive research has been focused on an immuno-
suppressant, 15-deoxyspergualin (gusperimus; Table 1 and
Additional File 1), and several active and less toxic analogues
of this molecule, such as LF08-0299 (tresperimus). These
molecules, the action mechanism of which is not fully
elucidated, interact with the constitutive HSC70/hsp73 heat
shock protein, expressed both intracellularly and at the
membrane, leading among other effects to the inhibition of
NF-κB nuclear translocation. 15-Deoxyspergualin was shown
to suppress the progression of polyclonal B-cell activation
and lupus nephropathy in lupus-prone MRL-lpr/lpr mice [4]. In
a short trial, however, two out of three treated SLE patients
showed nonsevere infectious episodes after 15-deoxy-
spergualin treatment [5].
Compounds targeting intracellular components
Targeting intracellular processes, such as signaling,
apoptosis or the cell cycle, may also represent an efficient
therapeutic method in SLE.
FKBP12-binding agents such as rapamycin (sirolimus,
rapamune) and tacrolimus (FK506), widely used as immuno-
suppressive agents, may represent interesting drugs to slow
down lupus disease progression. These two molecules
(Table 1, Additional File 1 and Figure 1) bind to the specific
cytosolic binding-protein FKBP12; but while tacrolimus
complexed to FKBP12 inhibits the Ca2+-dependent
phosphatase calcineurin, rapamycin-FKBP12 binds to and
inactivates mammalian target of rapamycin, a pivotal regulator
of cell growth and proliferation for many cell types. Other
effects of rapamycin include apoptosis, inhibition of T-cell
activation, inhibition of cell migration, and changes in
membrane trafficking. The fact that tacrolimus has been
shown to reduce the incidence of skin lesions in MRL-lpr/lpr
mice [6] and that it is used to control the symptoms of
eczema led to the proposal that tacrolimus might represent
an alternative to topical corticosteroid treatment in cutaneous
lupus. It has been recently reported that tacrolimus effectively
presents a significant efficacy, but randomized controlled
trials are needed to evaluate its safety and cost-effectiveness
[7]. Rapamycin was shown to prevent lupus in both NZB/W
and MRL-lpr/lpr mice, and preliminary results in nine SLE
patients revealed that rapamycin appears safe and effective in
patients who have been refractory to conventional treatments
[8]. A phase II study conducted by Wyeth Pharmaceuticals
(Madison, WI, USA) with the aim of prospectively determining
the therapeutic efficacy and action mechanisms of rapamycin
in patients with SLE is currently recruiting participants.
Induction of specific apoptosis that selectively kills auto-
reactive or inflammatory cells should also be considered to
slow down disease progression. As lupus T cells are abnor-
mally resistant to the induction of apoptosis, targeting this
population may represent an interesting alternative. Datta and
colleagues have demonstrated that resistance to apoptosis of
lupus T cells is related to an upregulation of cyclooxygenase
2, an enzyme involved in the formation of prostanoids [9].
Celecoxib (celebrex, celebra, controlled by Pfizer; Table 1
and Additional File 1), a cyclooxygenase-2 inhibitor, wasAvailable online http://arthritis-research.com/content/11/3/234
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Table 1
Compounds of interest as new tools for the treatment of systemic lupus erythematosus
Compound Product description Type of study Results/comments Reference
Atacicept Fusion protein (TACI-Ig)  Phase Ib, double-blind, placebo- Dose-dependent reduction in  [3]
B-lymphocyte stimulator  controlled, dose-escalating trial.  immunoglobulin levels and B-cell 
inhibition Patients with mild to moderate SLE  numbers. Well tolerated.
were enrolled.
15-Deoxyspergualin  Binds to HSC70/hsp73 heat  Case report: 3 SLE patients, safety  15-Deoxyspergualin was well  [5]
or gusperimus  shock protein evaluation. Treatment was performed  tolerated but 2/3 patients had 
by 9 cycles (1 cycle = 15-deoxy- nonsevere infectious episodes.
spergualin administration for 14 days 
with a break of 7 days).
FK506 or Tacrolimus  Inhibition of calcineurin Retroprospective review: analysis of  Efficacy in cutaneous lesions of  [7]
5 studies (only one randomized  SLE, but weaker efficacy in subacute 
controlled trial), including a total of  cutaneous LE or in discoid LE. 
60 SLE patients with cutaneous  Studies involving only a small number 
lesions. of patients and no control group.
Rapamycin/sirolimus/ mTOR inactivation Open-label study: 9 SLE patients  Reduction of BILAG score, of  [8]
rapamune  treated unsuccessfully with immuno- SLEDAI score and of prednisolone 
suppressive medications. Rapamycin  use compared with pre-rapamycin 
was given orally (2 mg/day). treatment.
Celecoxib or  Cyclooxygenase-2 inhibition Retrospective review of medical  Diminution of inflammation and good  [10]
celebrex  records for 50 patients treated with  safety profile.
celecoxib.
Prospective trial including  Reduction of SLEDAI score and no  [11]
51 patients. increase of coagulability.
Pentoxiphylline  Xanthine-derivative  Open-label study: 11 SLE patients  Decrease of proteinuria (from 5.5 to  [13]
phosphodiesterase inhibitor with refractory nephritis: class III, IV  2.0, P = 0.003). No patients 
or V, proteinuria ≥3 g/24 hours. discontinued the study due to side 
effects.
Tamoxifen  Estrogen antagonist Double-blind crossover trial:  No improvement of disease activity  [18]
11 females with stable SLE. and 2 patients deteriorated.
DHEA or prasterone  Androgen Review: analysis of randomized  Little clinical effect on disease  [20]
controlled trials (7) comparing  activity for patients with moderate 
DHEA with a placebo in SLE patients  disease.
(842 participants).
Modest but significant improvement 
in health-related quality of life.
Greater number of participants 
experiencing adverse events.
Fulvestrant or  Estrogen receptor  Double-blind, placebo-controlled:  Improvement of SLEDAI but not  [21]
faslodex  downregulator 20 premenopausal SLE women with  of serological markers, routine 
moderate SLEDAI received either  laboratory tests nor bone density. 
250 mg fulvestran intramuscularly  Medications for lupus reduced in 
for 12 months (10 patients) or  the fulvestrant group.
placebo (10 patients).
Bromocriptine  Dopamine agonist inhibition  Open-label trial: 7 active SLE patients  Serum prolactine and anti-dsDNA  [24]
of prolactine secretion treated daily during 6 to 9 months. suppressed, SLEDAI decreased 
(16 to 5.9).
Double-blind, randomized, placebo- Significant decreased of SLEDAI  [25]
controlled: 66 SLE patients  score (0.9 vs. 2.6 in control group), 
(36 bromocriptine, 30 placebo),  decreased mean number of 
treated daily and followed for 2 to  flares/patient/month (0.08 vs.
17 months. 0.18 in control group).
Continued overleafshown to induce apoptosis of lupus T cells ex vivo, leading in
co-cultures to the inhibition of autoAb production [9]. Results
from two clinical trials including SLE patients revealed that
the use of celecoxib, which presents a good safety profile,
was beneficial with, notably, a decrease of generalized
inflammation and a decreased SLEDAI score [10,11].
Cyclic nucleotide phosphodiesterase isoenzymes (11 families),
dedicated to cyclic AMP/GMP hydrolysis, play an important
role in physiological responses. The PDE4 family was described
as one of the major families controlling inflammation, and over
the past years the development of PDE4 inhibitors as anti-
inflammatory drugs has been a major focus of pharmaceutical
research. The administration of pentoxiphylline (Table 1 and
Additional File 1), a xanthine derivative and well-known
phosphodiesterase inhibitor, into MRL-lpr/lpr mice resulted in
a diminution of clinical parameters of the disease [12]. In an
open-label study including 11 lupus patients with renal
manifestations, pentoxiphylline was demonstrated to reduce
proteinuria [13]. Further investigations should thus be under-
taken to validate this interesting observation as all patients
were given immunosuppressants concomitantly.
Agents that modulate the hormonal pathway
Both sex steroid estrogen and pituitary hormones such as
prolactin are known to modulate autoimmunity and are thus
supposed to play a role in SLE. The involvement of hormones
in disease pathogenesis is supported by several obser-
vations: the prevalence of SLE is far higher in females than in
males; the onset of lupus often occurs in young, premeno-
pausal women; and males with SLE have low levels of
testosterone. The reduced secretion of anti-DNA Abs
following testosterone treatment highlights the critical role of
estrogen in the disease.
Modulation of sex steroid hormones
Treatment of NZB/W female mice with the estrogen antago-
nist tamoxifen (Table 1 and Additional File 1) significantly
reduces anti-DNA Ab production, ameliorates glomerulo-
nephritis and prolongs survival [14,15]. In MRL-lpr/lpr female
mice, tamoxifen alleviates disease activity, and treatment with
the selective estrogen receptor modulator LY139478
(Table 1 and Additional File 1) improves survival and retards
the progression of glomerulonephritis [16,17]. An open-label
study of 11 patients with SLE, however, did not demonstrate
any benefits of tamoxifen in ameliorating the clinical and
serological activity of SLE [18].
Improvement of the lupus disease in animal models with
androgen administration led investigators to also consider
dehydroepiandrosterone (Table 1 and Additional File 1) for
therapeutic use in lupus patients. Dehydroepiandrosterone
(DHEA) is a naturally occurring steroid and possesses both
endocrine and immunomodulatory effects. Interestingly,
serum levels of DHEA are decreased in SLE patients [19].
Several clinical studies have thus investigated the effect of
DHEA (G-701, prestara, prasterone) administration in lupus
patients. A comparison of these studies revealed that
whereas DHEA supplementation improved quality of life and
glucocorticoid requirements, the impact on disease activity
was inconsistent [20].
A double-blind placebo-controlled clinical trial recently
reported encouraging results in SLE women treated with an
estrogen-selective receptor downregulator named fulvestrant
(faslodex, developed by AstraZeneca Pharmaceuticals,
London, UK; Table 1 and Additional File 1). In patients who
received 250 mg fulvestrant intramuscularly for 12 months,
the SLEDAI score improved significantly and conventional
medications could be reduced [21].
Inhibition of prolactin
An increased frequency of hyperprolactinemia is observed in
patients with SLE, and elevated prolactin levels have been
correlated with clinical disease [22]. Prolactin administration
has been demonstrated to accelerate disease progression in
Arthritis Research & Therapy    Vol 11 No 3 Monneaux and Muller
Page 4 of 10
(page number not for citation purposes)
Table 1 (continued)
Compounds of interest as new tools for the treatment of systemic lupus erythematosus
Compound Product description Type of study Results/comments Reference
LJP394/abetimus  Toleragen molecule;  Phase III, randomized, placebo- Abetimus did not prolong time to  [27]
sodium/riquent  4 strands of ds-oligonucleo- controlled trial: 317 SLE patients  renal flare, time to initiation of 
tides (20-mer) linked  with a history of renal flares and  high-dose corticosteroid and/or 
through a triethylene  anti-dsDNA levels >15 IU/ml.  cyclophosphamide treatment, or 
glycol-based platform Patients received 100 mg/week for  time to major SLE flare, but 
up to 22 months. decreased anti-dsDNA antibody 
levels (P <0.0001).
Lupuzor  21-mer peptide P140  Phase IIa: open-label, dose-escalating  Diminution of anti-dsDNA antibody  [31]
RIHMVYSKRSGK (phosphoserine at  trial. 20 patients with moderate SLE  levels and of SLEDAI score in the 
PRGYAFIEY position 140) were enrolled. Lupuzor was given  group that received 200 μg peptide.
subcutaneously (200 μg or 1 mg).
Published trials only are presented. BILAG, British Isles Lupus Assessment Group; DHEA, dehydroepiandrosterone; ds, double-stranded; mTOR,
mammalian target of rapamycin; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.murine models of lupus (reviewed in [23]). Taken together,
these data showed that downregulation of the prolactin
production may represent an interesting way to treat SLE.
As prolactin secretion is inhibited by dopamine released from
the hypothalamus, the efficacy of bromocriptine (Table 1 and
Additional File 1), which is a dopamine agonist, was
evaluated in lupus. In an open-label trial including seven SLE
patients, it was shown that bromocriptine (3.75 to 7.5 mg/day
for 6 months) suppressed prolactin levels in all subjects and
improved clinical measurements in six of the seven treated
patients [24]. A double-blind, placebo-controlled study of
low-dose bromocriptine therapy (2.5 mg/day) showed a
significant decrease in prolactin levels associated with a
significant decrease in disease activity [25]. A pilot clinical
trial was recently conducted to explore the potential role of
oral bromocriptine during pregnancy [26]. Results showed
that bromocriptine may play a role in protecting pregnant
lupus patients from maternal and fetal complications.
Autoantigens
Among the outcome measures (endpoints) to be considered
in SLE trials are biomarker manifestations (for example, anti-
dsDNA Abs). During the past decade, a number of investi-
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Figure 1
Intracellular components targeted by non-antibody-directed therapeutics in lupus. Activation of the T-cell receptor (TCR) promotes a number of
signaling pathways, which may be targeted to treat systemic lupus erythematosus. Drugs that have been evaluated in lupus are indicated in red
boxes. Akt, protein kinase B; AP1, activator protein-1; APC, antigen-presenting cell; CDK, cyclin-dependent kinase; ERK, extracellular signal-
regulated kinase; IKK, IκB kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; mTOR, mammalian target of
rapamycin; NFAT, nuclear factor of activated T cells; NFκB, nuclear factor kappa B; PI3K, phosphatidylinositol 3-kinase; SP1, sphingosine-1-
phosphatase receptor; SYK, spleen tyrosine kinase; ZAP-70, z-chain associated protein kinase.gators have thus explored targeted strategies involving auto-
antigens in order to subvert or block key steps of the disease.
Promising data have been raised in murine models of lupus,
and a few therapeutic trials are currently in progress.
Two peptides and one peptide construct have reached
advanced clinical trials in lupus patients. The efficacy of the
first peptide, hCDR1 (edratide, TV-4710), although extremely
promising in lupus mice, was found to be safe and well
tolerated but did not meet its primary endpoint in a
randomized, double-blind, placebo-controlled phase II clinical
trial conducted by Teva (Petach Tikva, Israel) in 340 SLE
patients who received the peptide weekly by a subcutaneous
route (PRELUDE trial).
The results of a second candidate, abetimus sodium (LJP394,
riquent) – evaluated in a randomized, placebo-controlled,
multicenter phase III trial – have been recently published [27]
(Table 1 and Additional File 1). Abetimus is a synthetic water-
soluble molecule consisting of four double-stranded oligo-
deoxyribonucleotides each attached to a nonimmunogenic
triethylene glycol backbone, a proprietary carrier platform
[28]. Originated by La Jolla Pharmaceuticals (San Diego, CA,
USA), abetimus is an immunomodulating agent that induces
tolerance in B cells directed against dsDNA by cross-linking
surface Abs potentially responsible for lupus nephritis. The
recent reported data showed that abetimus administrated at
100 mg/week for up to 22 months to patients with lupus
nephritis significantly reduced anti-dsDNA Ab levels but did
not significantly prolong the time to renal flare when
compared with placebo. Although multiple positive trends in
renal endpoints were observed in the abetimus treatment
group [27], it has been recently decided to halt further clinical
trials of this drug in lupus.
A third peptide-based strategy involving an autoantigen seg-
ment, peptide P140 (IPP-201101, lupuzor), holds promise
(Table 1 and Additional File 1). This phosphorylated peptide is
recognized by T cells from MRL-lpr/lpr mice and patients with
SLE [29,30]. Intravenous administration of P140 into MRL-
lpr/lpr mice was found to significantly improve their clinical and
biological manifestations and prolonged their survival, while
the nonphosphorylated analogue did not. The P140 peptide
was included in phase I and phase II clinical trials conducted
by ImmuPharma (Mulhouse, France). Peptide P140 was found
to be safe and well tolerated by subjects, and significantly
improved the SLEDAI score and biological status of lupus
patients who received three subcutaneous doses of 200 μg
peptide [31]. P140 peptide is currently being evaluated in a
phase IIb, double-blind, placebo-controlled, dose-ranging
study in Europe and Latin America to confirm the beneficial
effects observed in the phase IIa trial.
Experimental agents for lupus therapy
Beside agents that are presently evaluated in clinical trials in
patients with lupus, there are also a number of experimental
compounds used with success in murine studies that deserve
particular attention. They are described below because
hopefully some of them represent interesting candidates for
future clinical trials.
Compounds targeting intracellular components
Spleen tyrosine kinase, a cytoplasmic tyrosine kinase, is a key
mediator of immunoreceptor signaling in a variety of cells,
including B cells, mast cells, macrophages platelets, and
naïve mature T cells. The spleen tyrosine kinase-specific
inhibitor R406 (converted from the prodrug R788 developed
by Rigel Pharmaceuticals Inc., San Francisco, CA, USA),
given orally, reduced the renal pathology and prolonged
survival of prediseased NZB/W mice, and, more importantly,
of mice with established lupus nephritis [32]. Interestingly,
signaling in lupus T cells is not effected by ZAP-70 but
replaced by spleen tyrosine kinase, leading to an increased
calcium response upon T-cell receptor stimulation [33].
Although no clinical data from SLE lupus are yet available,
results from a recent phase II clinical trial including 189
patients with rheumatoid arthritis are encouraging [34]. The
use of small molecules inhibiting intracellular mitogen-
activated protein kinase and phosphoinoside 3-kinase
(enzymes that generate phosphatidylinositol diphosphate and
triphosphate after receptor stimulation) signaling pathways
has also been envisaged. Although the extracellular signal-
regulated kinase (a serine/threonine protein kinase of the
mitogen-activated protein kinase family) inhibitor FR180204
was recently described as a new therapeutic approach in
rheumatoid arthritis [35], the use of such molecules in lupus
could be hampered by the fact that the mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase
pathway is reduced in lupus T cells [36]. In contrast, several
studies have demonstrated that phosphoinoside 3-kinase
gamma plays a crucial role in SLE, and encouraging results
have been obtained using MRL-lpr/lpr mice treated with
selective phosphoinoside 3-kinase gamma inhibitors, such as
AS605240 (a specific p110γ inhibitor) [37]. Promising
molecules targeting the phosphoinoside 3-kinase pathway
that have entered clinical trials for cancer therapy, inflam-
mation and coronary heart disease are described in a recent
review [38].
Molecules able to interfere with cell cycle should also be
considered as potential candidates in the development of
new lupus therapies. Cell cycle progression is controlled by
the activation of a heterodimer, formed by cyclins (regulatory
subunits) associated with cyclin-dependent kinases (catalytic
subunits; Figure 1). The effect of seliciclib (CYC202; Table 1
and Additional File 1), a cyclin-dependent kinase inhibitor that
is a trial drug currently tested in patients with solid tumors
and B-cell malignancies, was recently evaluated in NZB/W
lupus mice [39]. When administered in the early stages of the
disease, seliciclib was shown to delay the development of
proteinuria, to reduce the production of anti-dsDNA Abs, and
Arthritis Research & Therapy    Vol 11 No 3 Monneaux and Muller
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use of a cell cycle peptide inhibitor, the p21Waf/Cip1 mimic
[40]. As the expression of the cyclin-dependent kinase
inhibitor p21Waf/Cip1 is decreased in lymphocytes of lupus
patients [41], the use of such inhibitors could represent an
attractive route for treatment.
Other agents for which efficacy has been already established
in murine models of lupus may offer interesting therapeutic
avenues in the future. The ubiquitin–proteasome pathway is
involved in intracellular protein turnover and its function is
crucial to cellular homeostasis. Bortezomib (a proteasome
inhibitor marketed as Velcade by Millennium Pharmaceuticals,
Cambridge, MA, USA; Table 1 and Additional File 1) has thus
been successfully used in multiple myeloma. By blocking IκB
degradation, bortezomib induces the inhibition of NF-κB and
increases apoptosis of leukemia cells. These results led
investigators to evaluate the efficacy of bortezomib for the
depletion of plasma cells in lupus. Bortezomib treatment of
NZB/W and MRL-lpr/lpr lupus mice efficiently depleted
plasma cells, reduced autoAbs production, ameliorated
glomerulonephritis and prolonged survival [42]. It was
recently shown that inhibiting proteasome does induce the
apoptosis of activated CD4+ T cells, indicating that targeting
proteasome activity in lupus may represent an interesting
molecular strategy for targeting both autoreactive B cells and
T cells.
Histone acetylation is an important regulator of gene
expression, and therefore interfering with histone deacetyl-
ation could represent an interesting strategy to modulate
altered gene expression in lupus. Histone deacetylase
inhibitors have been used to reduce the disease in murine
models of lupus. In MRL-lpr/lpr mice, tricostatin A (Table 1
and Additional File 1) was found to decrease inflammatory
cytokine production by splenocytes and reduce renal disease
[43]; suberoylanilide hydroxamic acid was also shown to
modulate lupus progression [44]. These experimental data
suggest that histone deacetylase inhibitors might have
therapeutic interest to treat SLE.
Compounds inhibiting soluble molecules
In lupus, the loss of self-tolerance leads to the persistence
and activation of autoreactive B cells and T cells with the
consecutive abnormal secretion of cytokines and production
of autoAbs. The formation of immune complexes and the
activation of the complement pathway also play a major role
in disease pathogenicity. These soluble proteins are thus
interesting target candidates for the development of novel
lupus therapies.
The activation of the complement pathway in lupus amplifies
both immune and inflammatory responses and is involved in
the renal pathology. Apart from the use of anti-C5 monoclonal
Abs, the recent development of a molecule able to interfere
with both alternative and classical complement pathways and
that protects MRL-lpr/lpr mice from the disease is
encouraging [45]. This therapeutic agent, named CR2-Crry,
corresponds to a fusion protein that links the C3-binding
region of complement receptor 2 (CR2) to the complement
receptor 1-related protein y (Crry). Crry is similar to human
complement receptor 1 and inhibits C3 convertases of all
pathways. Complement inhibition in MRL-lpr/lpr mice with
Crry as a recombinant protein (Crry-Ig) protected animals
from renal disease but had no effect on survival [46], whereas
CR2-Crry treatment reduced glomerulonephritis, renal vascu-
litis, skin lesions and autoAb production associated with a
significant survival benefit. Importantly, and contrary to obser-
vations with Crry-Ig, CR2-Crry did not increase the levels of
circulating immune complexes, offering another advantage to
its development for controlling the human disease.
Several cytokines have been identified as major targets in
lupus, leading to the development of numerous mAbs, some
of them currently used in therapy or under clinical evaluation.
Another approach was recently developed, based on active
immunotherapy, which consists of inducing Abs able to
neutralize the interaction of the self-cytokine to its receptor. In
a mouse model for rheumatoid arthritis (transgenic mice
expressing human TNFα), it was demonstrated that vaccina-
tion with a biologically inactive but immunogenic human
TNFα derivative (keyhole limpet hemocyanin–human TNFα
heterocomplex), led to the production of high titers of Abs
that neutralize human TNFα bioactivity. Moreover, immunized
transgenic mice were protected from spontaneous arthritis
[47]. As cytokine network dysregulation is highly complex in
lupus, further investigations are needed to evaluate whether
this strategy may be advantageous in SLE in the future.
FTY720 (fingolimod), a high-affinity agonist of sphingosine-1-
phosphate type 1 receptor that induces the internalization of
the receptor, thus depriving cells from normal binding of
soluble sphingosine-1-phosphate type 1, is effective in
several murine models of lupus. The agonist was found to
suppress the development of autoimmunity and to prolong
the lifespan of female MRL-lpr/lpr mice [48]. FTY720 acts
primarily by sequestering lymphocytes within peripheral
lymphoid organs, rendering them incapable of migrating to
the sites of inflammation. Phase I, phase II and phase III
clinical trials have been conducted mostly in patients with
multiple sclerosis (Novartis, Basel, Switzerland) (reviewed in
[49]). Results are not yet available for patients with SLE.
Autoantigens
As described above, peptides encompassing autoantigen
sequences represent interesting tools to specifically target
autoreactive cells. Beside the peptides currently evaluated for
their efficacy in lupus, other peptides hold promise as they
gave interesting results in murine models of lupus.
Peptides corresponding to complementary-determining regions
(CDRs) in the heavy chain variable domain of autoAbs to
Available online http://arthritis-research.com/content/11/3/234
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NZB/W mice. These are, for example, the so-called 15-mer
pCONS peptide, a consensus of sequences derived from the
immunoglobulin heavy chain variable region (CDR1 and
second framework FR2) of several different NZB/W Abs to
DNA [50], or peptides derived from the sequence of the CDR1
and CDR3 (pCDR1, pCDR3) of a murine anti-DNA mAb that
bears the so-called 16/6 idiotype [51]. Tolerization of NZB/W
mice to monthly intravenous injections of 1 mg pCons
significantly delayed the appearance of multiple Abs and
nephritis, and dramatically prolonged survival of treated mice.
Tolerization with pCons, which contains MHC class I and II
T-cell determinants, was shown recently to activate different
subsets of inhibitory/cytotoxic CD8+ T cells that regulate both
CD4+CD25– effector T cells and B cells [52]. The tolerogenic
19-mer human CDR1 (hCDR1) peptide designed by Mozes
and colleagues was found to interfere with murine lupus
disease via the induction of CD4+CD25+ regulatory T cells,
and suppression involves CD8+CD28– regulatory T cells [53].
As mentioned above, however, this peptide did not give
expected results when evaluated in lupus patients.
Regarding peptides from nuclear autoantigens, Datta and
colleagues showed that repeated intravenous or intra-
peritoneal administration into (SWRxNZB)F1 (SNF1) lupus
mice with established glomerulonephritis of a single peptide
of histone H4 (sequence 16 to 39), which behaves as a
promiscuous T-cell epitope, prolonged survival of treated
animals and halted progression of renal disease [54]. The
protective properties of another peptide of histone H4
(sequence 71 to 93), accompanied by an increased level of
IL-10 and suppression of IFNγ secreted by lymph node cells,
were described in SNF1 mice administrated by the intranasal
route [55]. Following intranasal (but not intradermal) adminis-
tration of H4 peptide 71 to 93, the number of CD4+CD25+
regulatory T cells, which is low in NZB/W and SNF1 mice as
compared with normal mice, was restored in both strains
[56]. Very low-dose therapy (1 μg given subcutaneously
every 2 weeks) of SNF1 mice with H4 peptide 71 to 94 was
also found to induce CD8+ and CD4+CD25+ regulatory
T cells, to decrease IFNγ levels secreted by pathogenic
T cells, and to decrease the Ab levels by 90 to 100% [57].
The histone H3 peptide 111 to 130 encompassing a T-cell
epitope in NZB/W mice was used with success when
administrated intradermally in Freund’s adjuvant into these
mice [58]. Treatment of MRL-lpr/lpr mice with a 21-mer
peptide of the laminin α-chain targeted by lupus Abs also
prevented Ab deposition in the kidneys, ameliorated renal
disease, decreased the weight gain caused by accumulating
ascitic fluid and markedly improved the longevity of treated
mice [59].
Prospectives
Recent publications describing the successful use of new
therapeutic agents in murine models support their further
evaluation as therapies for SLE. In lupus, therefore, the
therapeutic potential of targeting Toll-like receptors (TLRs) is
supported by recent studies involving TLR7 and TLR9.
Nonstimulatory DNA sequences, able to inhibit TLR7 and
TLR9 activation and referred to as immunoregulatory DNA
sequences, have been identified. Interestingly, the adminis-
tration of one of these immunoregulatory DNA sequences to
NZB/W mice significantly reduced autoAbs production and
proteinuria, and increased survival [60].
In MRL-lpr/lpr mice, the administration of a synthetic G-rich
DNA (named ODN 2114) known to block CpG-DNA effects
led to less autoimmune tissue injury in the lungs and kidneys,
accompanied by decreased serum levels of anti-dsDNA
IgG2a Abs and of IFN-α [61]. The fact that chronic over-
production of IFNα may represent another marker for disease
activity in lupus [62] underlines the interest for the evaluation
of such immunoregulatory DNA sequences in SLE patients.
Statins are also considered with great interest since it was
demonstrated that these cholesterol-lowering drugs have
immunomodulatory properties. Additional studies are required
to investigate the potential use of statins in lupus, however,
as contradictory results were obtained in NZB/W mice that
were given atorvastatin, either orally or intraperitoneally.
Conclusions
The current literature search shows a number of promising
molecules that are impressively efficient in murine models of
lupus. These widely used mouse models are of first impor-
tance to identify decisive novel targets, to examine newly
developed therapeutic tools and to determine/clarify the
mode of action of these new molecules in vivo. Clearly,
however, very few of these molecules reach the standard
required for evaluating them in clinical trials involving patients
with SLE (their solubility and bioavailability, in certain cases,
can represent an important limitation). Moreover, because
SLE is a syndrome with multiple manifestations, both clinical
and biological, management and endpoint determinations of
clinical trials for SLE are complex. In particular, a central
question concerns the validity of biomarkers (and surrogate
markers) and activity indices, which are pertinent for
evaluating the performance of lupus trials [63,64].
Important progress has been made recently with the
publication of guidelines aimed at facilitating and better
controlling clinical trials for SLE [65]. Managing patients with
SLE is challenging and new treatments are eagerly awaited.
Establishing a valuable and solid data monitoring of patients
is as crucial as designing and developing safe and efficient
therapeutic molecules or biologicals.
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